TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03567824: A Phase 2 Open Label Study of Magnesium L-Lactate Dihydrate (MLD10) 10 mEq Extended-Release Caplets Administered BID for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus Followed by a Blinded Random

Sponsor: Pharmalyte Solutions LLC · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 200 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT03567824 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03567824 Rescue Dossier →